Biogen Amevive facility approved
Executive Summary
Biogen receives FDA approval for 90,000 liter manufacturing plant to produce psoriasis drug Amevive (alefacept). The 250,000 square foot facility, located in Research Triangle Park, N.C., brings Biogen's capacity for mammalian cell products to 106,000 liters; a 90,000 liter facility is under construction by Idec. FDA approved the biologic for marketing in January (1"The Pink Sheet" Feb. 3, 2003, p. 3)...